Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic CD19-STAR T Cells for Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
NCT06321289Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Mar 2024
- Primary completion
- Mar 2026
- Modality
- CRISPR-Cas9, TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Allogeneic CD19-STAR T cell in B-cell non-Hodgkin lymphoma, sponsored by Chinese PLA General Hospital. Primary endpoints: Incidence of Dose Limiting Toxicity at 12 months, Recommended Phase 2 Dose at 12 months and 1 more. Started Mar 2024; status: recruiting.
02
Drugs
Allogeneic CD19-STAR T cell
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06321289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06321289.